{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:18:15Z","timestamp":1791332295071,"version":"4.3.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T00:00:00Z","timestamp":1768003200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"vor","delay-in-days":27,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Obsessive-compulsive disorder (OCD) is a chronic psychiatric condition for which a substantial proportion of patients do not respond adequately to first-line treatments. This review thus aimed to critically appraise the clinical literature examining memantine in obsessive-compulsive disorder, with a particular focus on individual study design, dosing strategies, tolerability, and methodological limitations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A structured literature search of MEDLINE was conducted in March 2024 from database inception to March 2024. Titles, abstracts, and full texts were screened against predefined inclusion criteria, and relevant studies were synthesised narratively. A second, identical literature search was conducted in August 2025 covering March 2024 to August 2025. In total, 10 studies were included in the narrative synthesis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Our findings suggest that memantine may offer therapeutic benefits for OCD. Methodological issues, however, such as small sample sizes, strong geographical clustering, the exclusion of dropout data and limited use of intention-to-treat analyses, restrict the generalisability of the reported outcomes. Tolerability varied significantly by dose, with higher doses being associated with increased side effects while lower doses appeared better tolerated but elicited a poorer efficacy, although evidence was mixed. Only one study rigorously assessed treatment-refractory OCD and reported significant symptomatic improvement following longer-term memantine administration. Baseline severity, treatment expectancy, and concurrent cognitive-behavioural therapy were also identified as factors that may mediate these effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Overall, current evidence does not support the routine use of memantine for OCD. However, it does highlight specific methodological considerations and priorities for future rigorous investigation. Future randomised controlled trials with larger samples, longer follow-ups, and standardised dosing protocols are needed to clearly determine memantine\u2019s role in OCD management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial number<\/jats:title>\n                    <jats:p>Not applicable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12888-026-07787-7","type":"journal-article","created":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T15:53:42Z","timestamp":1768060422000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Memantine for the treatment of obsessive-compulsive disorder: a systematic review and narrative synthesis"],"prefix":"10.1186","volume":"26","author":[{"given":"Joshua W.","family":"Bryan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios","family":"Hassoulas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,10]]},"reference":[{"key":"7787_CR1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"2013","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders, (5th ed). In: Diagnostic and statistical manual of mental disorders; 2013. https:\/\/doi.org\/10.1176\/appi.books.9780890425596.","edition":"5th"},{"key":"7787_CR2","unstructured":"World Health Organization. International classification of diseases for mortality and morbidity statistics (11th revision). 2018. Available at: https:\/\/icd.who.int\/browse\/2024-01\/mms\/en."},{"key":"7787_CR3","doi-asserted-by":"crossref","unstructured":"Feusner JD, Kerwin L, Saxena S, Bystritsky A. Differential efficacy of memantine for obsessive-compulsive disorder vs. generalized anxiety disorder: an open-label trial. Psychopharmacol Bull. 20;42(1).","DOI":"10.64719\/pb.4096"},{"issue":"13","key":"7787_CR4","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1001\/jama.2017.2200","volume":"317","author":"ME Hirschtritt","year":"2017","unstructured":"Hirschtritt ME, Bloch MH, Mathews CA. Obsessive-compulsive disorder: advances in diagnosis and treatment. JAMA. 2017;317(13):1358\u20131358. https:\/\/doi.org\/10.1001\/jama.2017.2200.","journal-title":"JAMA"},{"issue":"41","key":"7787_CR5","doi-asserted-by":"publisher","first-page":"5647","DOI":"10.2174\/0929867325666171222163645","volume":"25","author":"U Albert","year":"2019","unstructured":"Albert U, Marazziti D, Di Salvo G, Solia F, Rosso G, Maina G. A systematic review of evidence-based treatment strategies for obsessive- compulsive disorder resistant to first-line pharmacotherapy. Curr Med Chem. 2019;25(41):5647\u201361. https:\/\/doi.org\/10.2174\/0929867325666171222163645.","journal-title":"Curr Med Chem"},{"issue":"2","key":"7787_CR6","doi-asserted-by":"publisher","first-page":"187","DOI":"10.31887\/dcns.2010.12.2\/mkellner","volume":"12","author":"M Kellner","year":"2010","unstructured":"Kellner M. Drug treatment of obsessive-compulsive disorder. Dialogues Clin Neurosci. 2010;12(2):187\u201397. https:\/\/doi.org\/10.31887\/dcns.2010.12.2\/mkellner.","journal-title":"Dialogues Clin Neurosci"},{"issue":"1","key":"7787_CR7","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/wps.20299","volume":"15","author":"D Mataix-Cols","year":"2016","unstructured":"Mataix-Cols D, Fern\u00e1ndez L, Nordsletten AE, Lenhard F, Isomura K, Blair Simpson H. Towards an international expert consensus for defining treatment response, remission, recovery and relapse in obsessive-compulsive disorder. World Psychiatry. 2016;15(1):80\u201381. https:\/\/doi.org\/10.1002\/wps.20299.","journal-title":"World Psychiatry"},{"key":"7787_CR8","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/b978-0-443-19176-3.00011-x","volume-title":"Rosenberg\u2019s molecular and genetic basis of neurological and psychiatric disease","author":"SB Abdallah","year":"2025","unstructured":"Abdallah SB, Olfson E, Fernandez TV. Obsessive-compulsive disorder. In: Rosenberg\u2019s molecular and genetic basis of neurological and psychiatric disease. Vol. 2; 2025. p. 937\u201350. https:\/\/doi.org\/10.1016\/b978-0-443-19176-3.00011-x."},{"key":"7787_CR9","doi-asserted-by":"publisher","unstructured":"Li Y, et al. Investigation of anterior cingulate cortex gamma-aminobutyric acid and glutamate-glutamine levels in obsessive-compulsive disorder using magnetic resonance spectroscopy. BMC Psychiatry. 2019;19(1). https:\/\/doi.org\/10.1186\/s12888-019-2160-1.","DOI":"10.1186\/s12888-019-2160-1"},{"issue":"6","key":"7787_CR10","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1080\/00048670802050546","volume":"42","author":"M Yucel","year":"2008","unstructured":"Yucel M, et al. Anterior cingulate glutamate-glutamine levels predict symptom severity in women with obsessive-compulsive disorder. Aust N Z J Psychiatry. 2008;42(6):467\u201377. https:\/\/doi.org\/10.1080\/00048670802050546.","journal-title":"Aust N Z J Psychiatry"},{"issue":"2","key":"7787_CR11","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.jpsychires.2012.09.015","volume":"47","author":"A Ghaleiha","year":"2013","unstructured":"Ghaleiha A, et al. Memantine add-on in moderate to severe obsessive-compulsive disorder: randomized double-blind placebo-controlled study. J Psychiatric Res. 2013;47(2):175\u201380. https:\/\/doi.org\/10.1016\/j.jpsychires.2012.09.015.","journal-title":"J Psychiatric Res"},{"issue":"6","key":"7787_CR12","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1055\/s-0043-120268","volume":"51","author":"A Modarresi","year":"2017","unstructured":"Modarresi A, Sayyah M, Razooghi S, Eslami K, Javadi M, Kouti L. Memantine augmentation improves symptoms in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder: a randomized controlled trial. Pharmacopsychiatry. 2017;51(6):263\u201369. https:\/\/doi.org\/10.1055\/s-0043-120268.","journal-title":"Pharmacopsychiatry"},{"issue":"3","key":"7787_CR13","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/0014-2999(89)90385-3","volume":"166","author":"J Bormann","year":"1989","unstructured":"Bormann J. Memantine is a potent blocker of N-methyl-D-aspartate (NMDA) receptor channels. Eur J Pharmacol. 1989;166(3):591\u201392. https:\/\/doi.org\/10.1016\/0014-2999(89)90385-3.","journal-title":"Eur J Pharmacol"},{"key":"7787_CR14","doi-asserted-by":"publisher","unstructured":"Marinova Z, Chuang D-M, Fineberg N. Glutamate-modulating drugs as a potential therapeutic strategy in obsessive-compulsive disorder. Curr Neuropharmacol. 2017;15(7). https:\/\/doi.org\/10.2174\/1570159x15666170320104237.","DOI":"10.2174\/1570159x15666170320104237"},{"key":"7787_CR15","unstructured":"NHS. Memantine. 2022. Available at: https:\/\/www.nhs.uk\/medicines\/memantine\/. Accessed 7 Aug 2025."},{"issue":"1","key":"7787_CR16","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1097\/jcp.0b013e318192e9a4","volume":"29","author":"E Aboujaoude","year":"2009","unstructured":"Aboujaoude E, Barry JJ, Gamel N. Memantine augmentation in treatment-resistant obsessive-compulsive disorder. J Clin Psychopharmacol. 2009;29(1):51\u201355. https:\/\/doi.org\/10.1097\/jcp.0b013e318192e9a4.","journal-title":"J Clin Psychopharmacol"},{"key":"7787_CR17","doi-asserted-by":"publisher","unstructured":"Askari S, Mokhtari S, Vahid Shariat S, Shariati B, Yarahmadi M, Shalbafan M. Memantine augmentation of sertraline in the treatment of symptoms and executive function among patients with obsessive-compulsive disorder: a double-blind placebo-controlled, randomized clinical trial. BMC Psychiatry. 2022;22(1). https:\/\/doi.org\/10.1186\/s12888-021-03642-z.","DOI":"10.1186\/s12888-021-03642-z"},{"key":"7787_CR18","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.jpsychires.2018.07.008","volume":"104","author":"V Farnia","year":"2018","unstructured":"Farnia V, et al. Efficacy and tolerability of adjunctive gabapentin and memantine in obsessive compulsive disorder: double-blind, randomized, placebo-controlled trial. J Psychiatric Res. 2018;104:137\u201343. https:\/\/doi.org\/10.1016\/j.jpsychires.2018.07.008.","journal-title":"J Psychiatric Res"},{"issue":"4","key":"7787_CR19","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1007\/s00213-013-3067-z","volume":"228","author":"M Haghighi","year":"2013","unstructured":"Haghighi M, et al. In a double-blind, randomized and placebo-controlled trial, adjuvant memantine improved symptoms in inpatients suffering from refractory obsessive-compulsive disorders (OCD). Psychopharmacology. 2013;228(4):633\u201340. https:\/\/doi.org\/10.1007\/s00213-013-3067-z.","journal-title":"Psychopharmacology"},{"key":"7787_CR20","doi-asserted-by":"publisher","unstructured":"Mirzazadeh H, Ghaeminia Y, Mohamad Niaei A, Kamran M, Razeghian Jahromi L, Moshfeghinia R. Memantine augmentation of escitalopram in treatment of executive function among patients with obsessive-compulsive disorder (OCD): a double-blind placebo-controlled randomized clinical trial. BMC Psychiatry. 2025;25(1). https:\/\/doi.org\/10.1186\/s12888-025-06856-7.","DOI":"10.1186\/s12888-025-06856-7"},{"issue":"2","key":"7787_CR21","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1097\/jcp.0000000000000651","volume":"37","author":"A Sahraian","year":"2017","unstructured":"Sahraian A, Razeghian Jahromi L, Ghanizadeh A, Mowla A. Memantine as an adjuvant treatment for obsessive compulsive symptoms in manic phase of bipolar disorder. J Clin Psychopharmacol. 2017;37(2):246\u201349. https:\/\/doi.org\/10.1097\/jcp.0000000000000651.","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"7787_CR22","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1097\/jcp.0b013e3181c856de","volume":"30","author":"ES Stewart","year":"2010","unstructured":"Stewart ES, Jenike EA, Hezel DM, Egan Stack D, Dodman NH, Shuster L, et al. A single-blinded case-control study of memantine in severe obsessive-compulsive disorder. J Clin Psychopharmacol. 2010;30(1):34\u201339. https:\/\/doi.org\/10.1097\/jcp.0b013e3181c856de.","journal-title":"J Clin Psychopharmacol"},{"key":"7787_CR23","doi-asserted-by":"publisher","first-page":"152352","DOI":"10.1016\/j.comppsych.2022.152352","volume":"120","author":"P van Roessel","year":"2023","unstructured":"van Roessel P, Grassi G, Aboujaoude EN, Menchon JM, Van Ameringen M, Rodriguez CI. Treatment-resistant OCD: pharmacotherapies in adults. Compr Psychiatry. 2023;120:152352\u2013152352. https:\/\/doi.org\/10.1016\/j.comppsych.2022.152352.","journal-title":"Compr Psychiatry"},{"issue":"8","key":"7787_CR24","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.3390\/biom10081134","volume":"10","author":"T Kikuchi","year":"2020","unstructured":"Kikuchi T. Is memantine effective as an NMDA receptor antagonist in adjunctive therapy for schizophrenia? Biomolecules. 2020;10(8):1134\u20131134. https:\/\/doi.org\/10.3390\/biom10081134.","journal-title":"Biomolecules"},{"issue":"1","key":"7787_CR25","doi-asserted-by":"publisher","first-page":"26","DOI":"10.2174\/157015910790909511","volume":"8","author":"E Soto","year":"2010","unstructured":"Soto E, Vega R. Neuropharmacology of vestibular system disorders. Curr Neuropharmacol. 2010;8(1):26\u201340. https:\/\/doi.org\/10.2174\/157015910790909511.","journal-title":"Curr Neuropharmacol"},{"key":"7787_CR26","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jad.2022.03.047","volume":"306","author":"T-W Hsu","year":"2022","unstructured":"Hsu T-W, Chu C-S, Ching P-Y, Chen G-W, Pan C-C. The efficacy and tolerability of memantine for depressive symptoms in major mental diseases: a systematic review and updated meta-analysis of double-blind randomized controlled trials. J Affective Disord. 2022;306:182\u201389. https:\/\/doi.org\/10.1016\/j.jad.2022.03.047.","journal-title":"J Affective Disord"},{"issue":"6","key":"7787_CR27","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1002\/gps.2384","volume":"25","author":"RW Jones","year":"2010","unstructured":"Jones RW. A review comparing the safety and tolerability of memantine with the acetylcholinesterase inhibitors. Int J Geriatric Psychiatry. 2010;25(6):547\u201353. https:\/\/doi.org\/10.1002\/gps.2384.","journal-title":"Int J Geriatric Psychiatry"},{"key":"7787_CR28","doi-asserted-by":"publisher","unstructured":"Geerts H, Roberts P, Spiros A. Assessing the synergy between cholinomimetics and memantine as augmentation therapy in cognitive impairment in schizophrenia. A virtual human patient trial using quantitative systems pharmacology. Front Pharmacol. 2015;6. https:\/\/doi.org\/10.3389\/fphar.2015.00198.","DOI":"10.3389\/fphar.2015.00198"},{"issue":"4","key":"7787_CR29","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jaac.2015.01.011","volume":"54","author":"MH Bloch","year":"2015","unstructured":"Bloch MH, Storch EA. Assessment and management of treatment-refractory obsessive-compulsive disorder in children. J Am Acad Child Adolesc Psychiatry. 2015;54(4):251\u201362. https:\/\/doi.org\/10.1016\/j.jaac.2015.01.011.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"2","key":"7787_CR30","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.jbtep.2009.10.006","volume":"41","author":"MJ Boschen","year":"2010","unstructured":"Boschen MJ, Drummond LM, Pillay A, Morton K. Predicting outcome of treatment for severe, treatment resistant OCD in inpatient and community settings. J Behav Ther Exp Psychiatry. 2010;41(2):90\u201395. https:\/\/doi.org\/10.1016\/j.jbtep.2009.10.006.","journal-title":"J Behav Ther Exp Psychiatry"},{"issue":"4","key":"7787_CR31","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1176\/appi.focus.20220058","volume":"20","author":"A Pinto","year":"2022","unstructured":"Pinto A, Teller J, Wheaton MG. Obsessive-compulsive personality disorder: a review of symptomatology, impact on Functioning, and treatment. Focus. 2022;20(4):389\u201396. https:\/\/doi.org\/10.1176\/appi.focus.20220058.","journal-title":"Focus"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-026-07787-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-026-07787-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-026-07787-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:34:31Z","timestamp":1781627671000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12888-026-07787-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,10]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["7787"],"URL":"https:\/\/doi.org\/10.1186\/s12888-026-07787-7","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,10]]},"assertion":[{"value":"26 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish declaration"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"130"}}